Volume : 3, Issue : 3, JUN 2019

A Review on Current Scenario on Tuberculosis

Harsh Goel, Hiteshwar Sharma, Bharat Prashar

Abstract

Tuberculosis is an infectious disease which is caused by bacteria Mycobacterium tuberculosis. The disease is a communicable disease mostly transmitted from person to person, usually by inhaling bacteria-carrying air droplets. Tuberculosis most commonly affects the lungs, but it can also affect any other organ. In this review on tuberculosis includes an introduction that describes how the lungs are affected by bacilli to enter the body and then spread to the rest of the body. The infection doesn`t always result in disease. The human immune defense cells can check and control pathogens, so that progression to disease only occurs in about 15% of adults. But the infection may remain latent and can reactive at any time, also after decades if e.g. the immune system is weakened. If left untreated, tuberculosis is a life-threatening illness. This article describes important advances in tuberculosis epidemiology, microbiology, diagnosis, pathology, clinical pharmacology, treatment and prevention.

Keywords

Tuberculosis, Epidemiology, Pathophysiology and Treatment of Tuberculosis.

Article : Download PDF

Cite This Article

Article No : 13

Number of Downloads : 0

References

  1. Centers for Disease Control and Prevention. World TB day—March 24, 2007. MMWR Morb Mortal Wkly Rep. 2007; 56(11):245.

 

  1. Centers for Disease Control and Preven-tion. Trends in tuberculosis incidence, United States, 2006. MMWR Morb Mortal Wkly Rep. 2007; 56(11):245-250.

 

  1. Goldrick BA. Once dismissed, still rampant: tuberculosis, the second deadliest infectious disease worldwide. Am J Nurs. 2004; 104(9):68-70.

 

  1. Porth CM. Alterations in respiratory function: respiratory tract infections, neoplasms, and childhood disorders. In: Porth CM, Kunert MP. Pathophysiology: Concepts of Altered Health States. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:615-619.

 

  1. Lee RB, Li W, Chatterjee D, Lee RE. Rapid structural characterization of the arabinogalactan and lipoarabinomannan in live mycobacterial cells using 2D and 3D HR-MAS NMR: structural changes in the arabinan due to ethambutol treatment and gene mutation are observed. Glycobiology. 2005; 15(2):139-151.

 

  1. Joe M, Bai Y, Nacario RC, Lowary TL. Synthesis of the docosanasaccharide arabinan domain of mycobacterial arabinogalactan and a proposed octadecasaccharide biosyn-thetic precursor. J Am Chem Soc. 2007; 129 (32):9885-9901.

 

  1. American Thoracic Society and Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000; 161(4 pt 1):1376-1395.

 

  1. Global Tb report 2012, Geneva; WHO (HTTP:// WHO int/tb/ publication/ global-report/en/.

 

  1. Lawn SD, Zumla AI. TB Lanut 2011; 378: 57-72.

 

  1. Surveillance reports: reported tuberculosis in the United States, 2005. Centers for Disease Control and Prevention. http://www.cdc.gov/tb/surv/surv2005/default.htm.Published September 2006. Last reviewed May 18, 2008. Accessed January 28, 2009.

 

  1. Schwenk A, Hodgson L, Wright A, et al. Nutritional partitioning during treatmen of tuberculosis: gain in body fat but not in protein mass. Am J Clin Nutr. 2004; 79: 1006-1012.

 

  1. Anderson ST, Williams AJ, Brown JR, et al.Transmission of Mycobacterium tuberculo-sis undetected by tuberculin skin testing. Am J Respir Crit Care Med. 2006; 173:1038-1042.

 

  1. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003; 362:887-899.

 

  1. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005; 54(RR-17):1-141.

 

  1. Van Crevel R, Ottenhoff THM, van der Meer JWM. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002; 15: 294-309.

 

  1. Nicod LP. Immunology of tuberculosis. Swiss Med Wkly. 2007; 137(25-26):357-362.

 

  1. Chalco K, Wu DY, Mestanza L, et al. Nurses as providers of emotional support to patients with MDR-TB. Int Nurs Rev. 2006; 53(4):253-260.

 

  1. Van Crevel R, Ottenhoff THM, van der Meer JWM. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002; 15: 294-309.

 

  1. Nicod LP. Immunology of tuberculosis. Swiss Med Wkly. 2007; 137(25-26):357-362.

 

  1. Goyot-Revol V, Innes JA, Hackforth S,Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Resp Crit Care Med. 2006; 173:803-810.

 

  1. Nicod LP. Immunology of tuberculosis. Swiss Med Wkly. 2007; 137(25-26):357-362.

 

  1. Thrupp L, Bradley S, Smith P, Simor A, Gantz N, et al. Tuberculosis prevention and control in long-term-care facilities for older adults. Infect Control Hosp Epidemiol. 2004; 25:1097-1108.

 

  1. Interactive core curriculum on tuberculosis. Centers for Disease Control and Prevention http://www.cdc.gov/tb/webcourses/CoreCurr/TB_Course/Menu/frameset_internet.htm. Accessed January 28, 2009.

 

  1. Michos AG, Daikos GL, Tzanetou K, et al. Detection of Mycobacterium tuberculosis DNA in respiratory and nonrespiratory specimens by the Amplicor MTB PCR. Diagn Microbiol Infect Dis. 2006; 54:121-126.

 

  1. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis.

 

  1. Chalco K, Wu DY, Mestanza L, et al. Nurses as providers of emotional support to patients with MDR-TB. Int Nurs Rev. 2006; 53(4):253-260.

 

  1. TB elimination: the difference between latent TB infection and active TB disease. Centers for Disease Control and Prevention Web site. http://cdc.gov/tb/pubs/tbfactsheets/LTBIandActiveTB.pdf. Updated October 7, 2008. Accessed January 28, 2009.